Natixis Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Natixis Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,018	Closed	-$399K	–	1524
2022 Q4	$399K	Buy	12,018 +1,346	+13%	+$43.4K	﹤0.01%	1340
2022 Q3	$336K	Buy	+10,672	New	+$346K	﹤0.01%	1364
2019 Q2	–	Sell	-109,666	Closed	-$1.93M	–	1094
2019 Q1	$1.93M	Buy	109,666 +49,925	+84%	+$831K	0.02%	769
2018 Q4	$1.04M	Buy	+59,741	New	+$1.02M	0.01%	901

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Natixis Advisors's VIVO Position: Q1 2023 in Review

Natixis Advisors sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 12,018 shares — an estimated $399K sold.

Natixis Advisors first reported a position in VIVO in Q4 2018 and held it in 4 quarters. The position peaked at $1.93M in Q1 2019. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Natixis Advisors reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Natixis Advisors sold 12,018 Meridian Bioscience Inc shares in Q1 2023, an estimated $399K.
Natixis Advisors first reported a position in Meridian Bioscience Inc in Q4 2018 and held it in 4 quarters.
Natixis Advisors's Meridian Bioscience Inc position peaked at $1.93M in Q1 2019.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Natixis Advisors's 13F filing for Q1 2023, filed 11 May 2023.